vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Fatpipe Inc (FATN). Click either name above to swap in a different company.
Fatpipe Inc is the larger business by last-quarter revenue ($4.1M vs $3.9M, roughly 1.0× Citius Pharmaceuticals, Inc.). Fatpipe Inc runs the higher net margin — 7.6% vs -238.2%, a 245.8% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs FATN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.1M |
| Net Profit | $-9.4M | $310.7K |
| Gross Margin | 80.0% | 87.7% |
| Operating Margin | -228.7% | 9.8% |
| Net Margin | -238.2% | 7.6% |
| Revenue YoY | — | 3.2% |
| Net Profit YoY | 8.6% | 816.0% |
| EPS (diluted) | $-0.38 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.1M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $3.9M |
| Q4 25 | $-9.4M | $310.7K | ||
| Q3 25 | — | $-43.4K | ||
| Q2 25 | — | $741.2K |
| Q4 25 | 80.0% | 87.7% | ||
| Q3 25 | — | 92.1% | ||
| Q2 25 | — | 94.2% |
| Q4 25 | -228.7% | 9.8% | ||
| Q3 25 | — | -0.0% | ||
| Q2 25 | — | 25.5% |
| Q4 25 | -238.2% | 7.6% | ||
| Q3 25 | — | -1.1% | ||
| Q2 25 | — | 18.8% |
| Q4 25 | $-0.38 | $0.02 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | — |
| Total DebtLower is stronger | — | $4.6M |
| Stockholders' EquityBook value | $80.0M | $21.2M |
| Total Assets | $140.4M | $32.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — |
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $4.9M |
| Q4 25 | $80.0M | $21.2M | ||
| Q3 25 | — | $21.0M | ||
| Q2 25 | — | $20.4M |
| Q4 25 | $140.4M | $32.4M | ||
| Q3 25 | — | $32.2M | ||
| Q2 25 | — | $32.0M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.24× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $240.9K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $240.9K | ||
| Q3 25 | — | $399.8K | ||
| Q2 25 | — | $-508.6K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-551.1K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -14.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.1% |
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
FATN
| Products | $2.6M | 63% |
| Other | $1.5M | 37% |
